Skip to main content
. 2017 May 17;6(3):236–249. doi: 10.1159/000472262

Fig. 2.

Fig. 2

Kaplan-Meier plots of progression-free survival (PFS) after treatment commencement. The median PFS was 4.8 months for patients treated with HAIC, which was significantly better compared with that of patients treated with sorafenib (p = 0.0032, log-rank test).